- Home
- SRG vs ELDN Comparison
SRG vs ELDN Comparison
Compare SRG & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- ELDN
- Stock Information
- Founded
- SRG 2014
- ELDN 2004
- Country
- SRG United States
- ELDN United States
- Employees
- SRG N/A
- ELDN N/A
- Industry
- SRG Real Estate Investment Trusts
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- SRG Real Estate
- ELDN Health Care
- Exchange
- SRG Nasdaq
- ELDN Nasdaq
- Market Cap
- SRG 163.3M
- ELDN 178.4M
- IPO Year
- SRG 2015
- ELDN N/A
- Fundamental
- Price
- SRG $3.29
- ELDN $3.62
- Analyst Decision
- SRG
- ELDN Strong Buy
- Analyst Count
- SRG 0
- ELDN 2
- Target Price
- SRG N/A
- ELDN $12.50
- AVG Volume (30 Days)
- SRG 79.7K
- ELDN 880.0K
- Earning Date
- SRG 08-13-2025
- ELDN 08-18-2025
- Dividend Yield
- SRG N/A
- ELDN N/A
- EPS Growth
- SRG N/A
- ELDN N/A
- EPS
- SRG N/A
- ELDN N/A
- Revenue
- SRG N/A
- ELDN N/A
- Revenue This Year
- SRG N/A
- ELDN N/A
- Revenue Next Year
- SRG N/A
- ELDN N/A
- P/E Ratio
- SRG N/A
- ELDN N/A
- Revenue Growth
- SRG N/A
- ELDN N/A
- 52 Week Low
- SRG $2.43
- ELDN $2.38
- 52 Week High
- SRG $5.25
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- SRG 58.23
- ELDN 59.47
- Support Level
- SRG $3.20
- ELDN $3.63
- Resistance Level
- SRG $3.36
- ELDN $3.95
- Average True Range (ATR)
- SRG 0.14
- ELDN 0.24
- MACD
- SRG 0.01
- ELDN 0.01
- Stochastic Oscillator
- SRG 68.25
- ELDN 49.73
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.